Cargando…

Cerebrospinal Fluid Biomarkers for the Diagnosis and Classification of Alzheimer's Disease Spectrum

BACKGROUND: Cerebrospinal fluid (CSF) biomarkers are increasingly used in clinical practice for the diagnosis of Alzheimer's disease (AD). We aimed to 1) determine cutoff values of CSF biomarkers for AD, 2) investigate their clinical utility by estimating a concordance with amyloid positron emi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Jongmin, Jang, Hyemin, Kang, Sung Hoon, Kim, Jaeho, Kim, Ji Sun, Kim, Jun Pyo, Kim, Hee Jin, Seo, Sang Won, Na, Duk L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7669457/ https://www.ncbi.nlm.nih.gov/pubmed/33200589 http://dx.doi.org/10.3346/jkms.2020.35.e361

Ejemplares similares

Cerebrospinal fluid from Alzheimer’s disease patients as an optimal formulation for therapeutic application of mesenchymal stem cells in Alzheimer’s disease
por: Lee, Jeongmin, et al.
Publicado: (2019)

Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease in South Korea
por: Park, Sun Ah, et al.
Publicado: (2017)

Predicting amyloid positivity in patients with mild cognitive impairment using a radiomics approach
por: Kim, Jun Pyo, et al.
Publicado: (2021)

Distinctive Temporal Trajectories of Alzheimer’s Disease Biomarkers According to Sex and APOE Genotype: Importance of Striatal Amyloid
por: Kim, Jun Pyo, et al.
Publicado: (2022)

Prediction of tau accumulation in prodromal Alzheimer’s disease using an ensemble machine learning approach
por: Kim, Jaeho, et al.
Publicado: (2021)

Optical coherence tomography angiography as a potential screening tool for cerebral small vessel diseases
por: Lee, Ju-Yeun, et al.
Publicado: (2020)

Classification and prediction of cognitive trajectories of cognitively unimpaired individuals
por: Kim, Young Ju, et al.
Publicado: (2023)

The Cortical Neuroanatomy Related to Specific Neuropsychological Deficits in Alzheimer's Continuum
por: Kang, Sung Hoon, et al.
Publicado: (2019)

Differential effects of risk factors on the cognitive trajectory of early- and late-onset Alzheimer’s disease
por: Kim, Jaeho, et al.
Publicado: (2021)

Cerebrospinal Fluid Biomarkers for the Diagnosis of Prodromal Alzheimer's Disease in Amnestic Mild Cognitive Impairment
por: Park, Jung Eun, et al.
Publicado: (2019)

Identifying genetic variants for amyloid β in subcortical vascular cognitive impairment
por: Kim, Hang-Rai, et al.
Publicado: (2023)

Interaction between Alzheimer’s Disease and Cerebral Small Vessel Disease: A Review Focused on Neuroimaging Markers
por: Kim, Si Eun, et al.
Publicado: (2022)

Clinical outcomes of increased focal amyloid uptake in individuals with subthreshold global amyloid levels
por: Kim, Jaeho, et al.
Publicado: (2023)

Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges
por: Kim, Dana, et al.
Publicado: (2016)

The Correlation Study between Plasma Aβ Proteins and Cerebrospinal Fluid Alzheimer's Disease Biomarkers
por: Shin, Ho Sik, et al.
Publicado: (2016)

A Consensus in Korea Regarding a Protocol to Reduce Preanalytical Sources of Variability in the Measurement of the Cerebrospinal Fluid Biomarkers of Alzheimer's Disease
por: Park, Sun Ah, et al.
Publicado: (2015)

Identifying a subtype of Alzheimer’s disease characterised by predominant right focal cortical atrophy
por: Kim, Ko Woon, et al.
Publicado: (2020)

Machine learning based hierarchical classification of frontotemporal dementia and Alzheimer's disease
por: Kim, Jun Pyo, et al.
Publicado: (2019)

Disease progression modelling from preclinical Alzheimer’s disease (AD) to AD dementia
por: Cho, Soo Hyun, et al.
Publicado: (2021)

Role of Cerebrospinal Fluid Biomarkers in Clinical Trials for Alzheimer's Disease Modifying Therapies
por: Kang, Ju-Hee, et al.
Publicado: (2014)

On the reliability of deep learning-based classification for Alzheimer’s disease: Multi-cohorts, multi-vendors, multi-protocols, and head-to-head validation
por: Song, Yeong-Hun, et al.
Publicado: (2022)

The preclinical amyloid sensitive composite to determine subtle cognitive differences in preclinical Alzheimer’s disease
por: Hahn, Alice, et al.
Publicado: (2020)

Disease progression modeling of Alzheimer’s disease according to education level
por: Kim, Ko Woon, et al.
Publicado: (2020)

The effects of imaging markers on clinical trajectory in cerebral amyloid angiopathy: a longitudinal study in a memory clinic
por: Jang, Hyemin, et al.
Publicado: (2023)

Alzheimer’s Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid
por: Huynh, Rose Ann, et al.
Publicado: (2017)

Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome
por: Dekker, Alain D., et al.
Publicado: (2017)

Identification of potential biomarkers related to mesenchymal stem cell response in patients with Alzheimer’s disease
por: Choi, Yejoo, et al.
Publicado: (2023)

Frontal-executive dysfunction affects dementia conversion in patients with amnestic mild cognitive impairment
por: Jung, Young Hee, et al.
Publicado: (2020)

Effect of education on functional network edge efficiency in Alzheimer’s disease
por: Kim, Yeshin, et al.
Publicado: (2021)

Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer’s disease dementia: a phase I clinical trial
por: Kim, Hee Jin, et al.
Publicado: (2021)

Sex differences in the structural rich-club connectivity in patients with Alzheimer’s disease
por: Kim, Soo-Jong, et al.
Publicado: (2023)

Atrophy, metabolism and cognition in the posterior cortical atrophy spectrum based on Alzheimer's disease cerebrospinal fluid biomarkers
por: Montembeault, Maxime, et al.
Publicado: (2018)

Cortical neuroanatomical changes related to specific neuropsychological deficits in subcortical vascular cognitive impairment
por: Kang, Sung Hoon, et al.
Publicado: (2021)

Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease
por: Khoonsari, Payam Emami, et al.
Publicado: (2016)

SWATH-MS analysis of cerebrospinal fluid to generate a robust battery of biomarkers for Alzheimer’s disease
por: Park, Sun Ah, et al.
Publicado: (2020)

Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease
por: Irwin, David J., et al.
Publicado: (2020)

Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease
por: Babić, Mirjana, et al.
Publicado: (2014)

Cerebrospinal fluid neurogranin and YKL‐40 as biomarkers of Alzheimer's disease
por: Janelidze, Shorena, et al.
Publicado: (2015)

Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer’s Disease Diagnosis
por: Bjerke, Maria, et al.
Publicado: (2018)

Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: Their Role in Clinical Chemistry
por: Blennow, Kaj, et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_o5u77ch550d1tli58l1cgu191q